最新一代肺癌靶向药奥希替尼片（AZD9291）在2017年3月被国家食药总局批准上市，成为新药审批改革后上市审批时间最短的药物，这一药物专门针对由EGFR基因突变引起的非小细胞肺癌。

　　The new medicine AZD9291 aimed at lung cancers was approved to sell on the market by China Food and Drug Administration (CFDA) in March 2017. This medicine is the one that takes the shortest time to go through medical checks, after the reforms on new medicine approval procedures. It is specially designed to treat the non small cell lung cancers caused by the EGFR mutations.

　　据统计，我国每年新发病的肺癌患者超过73万，肺癌死亡人数超过61万，且在持续增加。即便是早期发现，肿瘤进展中会不可避免地产生耐药，导致疾病进一步进展。因此，每一代新药的出现都给了癌症患者延续生命的可能。

　　According to statistics, more than 730,000 people is diagnosed as lung cancer patients per year and the number of lung cancer deaths is more than 610,000 and keeps increasing. Even if the disease was found at an early stage, the treatment of the disease will unavoidably lead to drug resistance, which will worsen the disease. Therefore, every new medicine gives patients hopes to live longer.

　　“中国拥有全世界最多的EGFR突变患者，人数占全球近一半。大多接受一代、二代药物治疗的患者，会在治疗后一年左右耐药。随着精准医疗的进步，我们发现，大约三分之二的耐药患者出现T790M突变。”上海市胸科医院陆舜教授说，在我国，非小细胞肺癌患者约占肺癌病例总数的85%。

　　"China has more EGFR mutation patients than any other countries across the world, about half of the total. Those who received treatment of the first and second generation medicines usually begin to develop drug resistance about 1 year after the treatment. With the growth of precise medical  equipments, we found that two thirds of the patients with drug resistance experienced T790 mutations. "

　　一位服用原料药肺癌患者家属告诉南方周末记者，即便他们知道正版的药物已经上市，但仍不准备换了。因为这款药的国内售价每盒5.1万人民币（美国售价合人民币8万—9万），“吃不起，毕竟癌症患者的家庭也要维持生活。”

　　A relative of a patient who had lung cancer told Southern Weekly reporter that they would not buy the new medicine even though it was available on the market. The medicine cost 51,000￥(80000-90000￥in the USA) in China. "We cannot afford it. After all, we still had a life to live."